Novel method of treating ovarian infertility: is Platelet-Rich Plasma a new promising therapy in the future? by Stojkovska, Snezana et al.





Original article  
 
A NOVEL METHOD OF TREATING OVARIAN INFERTILITY: IS PLATELET-RICH PLASMA 




Snezhana Stojkovska, Gligor Dimitrov, Zoran Petanovski, Damjan Shushleski, Stefan Saltirovski, 
Vladimir Matevski, Makuli Hadzi Lega, Valentina Sotirovska, Daniela Stojanovska, Nikoleta 
Stamenkovska, Emilija Petanovska Kostova and Rina Latifi Isaki 
 




Introduction. In today's modern society, the treatment 
of patients with poor ovarian reserve presents a medi-
cal challenge of increased clinical importance. The use 
of platelet-rich plasma (PRP) is a new hope that improves 
pregnancy chances. Increased use of the PRP in a 
number of in vitro centers around the world as well as 
publication of thefirst experience in in vitro fertili-
zation entailed the need for this systematic review. 
Methods. PubMed, Cochrane and Ovid Medline were 
searched between 2000 and 2019 under the following 
strategy: [<PRP or plasma-rich with platelets> and <ovaries 
with reduced reserves or function> and <ovarian reju-
venation>]. Fourteen original articles published in me-
dical scientific journals were analyzed in this study. 
The evidence level and quality assessment were made 
based on the most up-to-date, reliable, scientific evidence 
as well as from the number of additional relevant citations. 
Results. Taking the current available proof and evidence 
into consideration, we can conclude that the PRP me-
thod improves the ovarian function and increases the 
chances of clinical pregnancy. In addition, we assume 
that, over time, the PRP method objectively improves 
the ovarian reserves. Recent studies support the theory 
of increasing the number of preantral follicles, follo-
wed byappropriate growth and reduction of follicular 
atresia. 
Conclusion. The improvement of the quantity and 
quality of oocytes with the intra-ovarian application of 
PRP potentially suggests a new concept of ovarian aging, 
where the ovarian microenvironment plays a crucial role. 
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Ovarian rejuvenation thorough history 
 
Oogenesis, the production, and development of the 
oocyte, is the principal role of the ovarian tissue. It 
was believed for a long time that women are born with 
certain reproductive potential which is in direct corre-
lation withthe number of primordial follicles produced 
during the time of embryological and fetal period and 
which progressively decrease to reach a number circa 
300 000 primordial follicles until the time of menarche 
[1]. These claims were altered by Tilly et al. by demon-
strating the existence of germ cells in the ovarian tissue 
[2]. He examined new concepts for how oocytes and 
their precursor cells might be altered metabolically to 
sustain or increase ovarian function and fertility in 
women [2]. This has led to the development of 
different methods and techniques through which the 
scientific circles are making endeavors to find the 
corresponding therapeutic method for patients with 
decreased ovarian reserves. 
The first research presented the use of dehydroepian-
drosterone (DHEA) as a food supplement that can 
have therapeutic benefits in treatment ofpatients with 
decreased ovarian reserves [3]. The success of DHEA has 
beenclinically proven in many studies and it remains 
one of the first noninvasive medical treatments for 
ovarian rejuvenation. The use of precursors of testo-
sterone can improve the ovarian microenvironment. 
DHEA reaches a maximum in people aged between 20 
to 30 years and decreases approximately 2% per year 
[4].  A similar concept brings the use of coenzyme Q 10. 
The role of this molecule is not conclusive in the 
improvement of the mitochondrial function caused by 
ageing of the tissue. The androgen supplements can 
also have positive effect on mitochondrial function [5]. 
Doctorsin multiple IVF centers in the USA recommend 
the transvaginal trauma of ovarian tissue, i.e. piercing, 
as a method for ovarian rejuvenation. This method is 
accompanied by changes in hormonal status, local 
immunological response and increased vascularization 
in the ovarian tissue. The trauma initiates growth fac-
tor production, which promotes tissue regeneration [6]. 
Furthermore, Bukovsky recommended novel methods 
of treating premature ovarian failure and ovarian infer-
tility. In hisstudy he has concluded that the follicular 
renewal is also dependent on the support of circulating 
blood mononuclear cells. The circulating mononuclear 
cells as a part of the immune system regulate the 
function of almost all tissues in the body, which leads 
to temporary rejuvenation of the endocrine and immune 
system in the ovarian tissue. Namely, the immune system 
plays a crucial role in the modulation of ovarian 
function, as it regulates ovarian development, follicu-
lar maturation, ovulation and formation of the corpus 
luteum [7, 8]. 
In recent years a new approach has emerged in the 
treatment of ovarian infertility based on the use of 
plasma rich with platelets (PRP) with or without stem 
cells as a method for ovarian rejuvenation and folli-
cular reactivation [9,10]. 
 
Material and methods 
 
We conducted a systematic search of PubMed, Cochrane 
and Ovid Medline databases from 2000 to 2019 using 
the following keywords: platelet-rich plasma, ovarian 
reserve or diminished ovarian reserve, ovarian function 
or diminished ovarian function, poor responders, rep-
roductive age, IVF. This search yielded 110 studies, of 
which 14 original articles and reviews were included. 
All publications were reviewed by the authors of this 
manuscript, who agreed onthe analysis and 
interpretation of data. Some of the studies have 
addressed the question of whether these approaches of 
transvaginal intraovarian application of PRP may be 
beneficial in poor responders with respect of clinical 
pregnancy and live birth rates in patients. Studies were 
eligible if they met one of the following criteria: 
primary evidence (clinical trials) that assessed the 
effectiveness of a procedure correlated with an outcome 
measurement (pregnancy, IVF, live birth rates); meta-
analyses; and relevant articles from bibliographies of 
identified articles. The level of evidence was evaluated 
using the grading system available online and 
wasassigned for each reference in the bibliography. 
The quality of evidence was evaluated using the grading 
system, adapted from Johns Hopkins Nursing 




The first description of PRP was introduced as a 
preparation consisting of concentrated platelets in a 
limited plasma volume. It is used in various regene-
ration procedures of surgical tissues, where growth 
factors from platelets can affect the speeding up of 
growth factors (GFs) contained in platelet alpha granu-
les are a major part of the PRP. They induce, through 
appropriate transmembrane receptors in target cells, a 
whole range of intracellular processes leading to proli-
feration, differentiation, matrix formation, osteoid pro-
duction, collagen synthesis, haemostasis, and everything 
that leads to tissue recovery and regeneration. It is 
noted that the mitogen effects of PRP are only limited 
to augmentation of the normal healing process and is 
theoretically not mutagenic, as the GFs released do not 
enter the cell or its nucleus, but only bind to the 
membrane receptors and induce signal transduction 
mechanisms (Table 1) [12]. 
 





Table 1. Platelet growth factors and their specific characteristics 
 
(Principles and Methods of Preparation of Platelet-Rich Plasma: a Review and Authors Perspective:  2014. Journal of Cutaneous and 
Aesthetic Surgery  Oct-Dec 2014, Volume 7, Issue 4) 
 
In recent years the effect of autologous platelet-rich 
plasma has beenincreasingly used in the treatment of 
any injuries of the soft and connecting tissues as well 
as the bone grafts. The use of PRP is a significant part 
of the speed-up healing process of the injured tissue, 
angiogenesis and tissue remodeling - with this, the use 
of PRP has become a routine treatment in orthopedics, 
dermatology, and specific autoimmune diseases [13, 14].  
Many clinicans have noticed that the use of PRP 
improves the function of the target organ, which 
resulted in an enthusiastic use of PRP in patients with 
ovarian insufficiency. Studies have shown that many 
innovative techniques find their way from theory to 
practice. Namely, the use of PRP in restoring both the 
reproductive and endocrine functions of the ovary was 
presentedin a study from 2017 by Ljubic. He described 
the first case of ahuman embryo obtained after auto-
logous ovarian in vitro activation with orthotopic re-
transplantation [15]. The novel application of PRP in 
the ovarian cortex was pioneered by Pantos [9]. The 
idea of potential therapeutic use of autologous PRP in 
the renewal of egg cells and follicular reactivation was 
published in 2017, via the first abstract and detailed 
oral report on PRP as a method of renewal of egg cells 
atthe ESHREmedical conference. 
During the following year, 2018, an increase in oocytes 
and embryo quality was also confirmed inScott's study 
[10]. This pilot study was focused on the intra-ovarian 
injection of the autologous plasma enriched with 
thrombocytes and the effect of PRP on the ovarian 
microenvironment and the creation of oocytes of de-
cent/high quality. Melo's study has confirmed the effi-
cacy of using an intracortical ovarian injection of PRP 
that significantly improves ovarian reserve and sub-
sequent reproductive outcome in infertile women [16]. 
The effects of autologous PRP were observed in the 
treatment of repeated implantation failure in IVF cycles 
in order to improve pregnancy outcome [17]. It is 
considered that one of the mechanisms bywhich PRP 
results in changes in the ovarian reserves and the 
activation of the primary preantral follicles is through 
the synergy connection of the factors for growth con-
tained in the PRP with the usage of gonadotropins for 
ovarian stimulation.  
In women considered to be poor ovarian responders, 
there is insufficient evidence forrecommending or rejec-
ting intraovarian injection of autologous PRP before 




It remains essential to understand the physiological 
basis of ovarian aging to interpret the mechanisms of 
action. With the use of platelet-derived growth factors 
(PDGFs), dysfunctional ovarian tissue is believed to 
be supplied with essential factors necessary for ovarian 
regeneration. In this context, it is necessary to mention 
angiogenesis and follicular vascularization and their 
important role in the aging of the follicles. Receptors 
for growth factors are present on granulose cells con-
firming their association with the activation process of 
the primordial follicles. The most important component 
in PRP is the transforming growth factor-beta family 
(TGF beta) that plays a significant role during the de-
velopmental phases of the follicle [18]. Confirmation 
of all the above statements is also obtained from the 
 





Hosseini study [19]. This study evaluated the effects 
of platelet-rich plasma (PRP) on the growth and 
survival of isolated early human follicles in a three-
dimensional culture system. The conclusion was that 
media supplementation with PRP could better support 
the viability and growth of isolated human preantral 
follicles in vitro. 
On the other hand, the presence of OSCs on the 
surface of the ovarian tissue, under certain conditions, 
can produce de novo primordial follicles and thus the 
appearance of new antral follicles. It is noteworthy to 
mention that only a fraction of OSCs undergoes 
meiosis culture to form oocytes. It remains unknown 
why only a few cells express Stra8 and undergo differ-
rentiation [20]. Alternatively, it is possible that OSC 
aging is a result of impaired DNA double-strand break 
repair, a recently identified cause of aging in mammalian 
oocytes. Elucidating the mechanisms that cause OSCs 
to age could lead to new treatments that could delay 
ovarian aging and slow infertility. Also, several ques-
tions about the PRP's mechanism of action remain 
unanswered. 
 
PRP activation and intraovarian application  
 
According to the results in the literature different pro-
tocols which describe the optimal conditions needed 
for preparation of autologous PRP are detailed. The 
relative centrifugal force, time temperature, the use of 
anticoagulants and the method of activation of the PRP 
can influence the preparation of the autologous PRP 
[13, 14]. 
the platelets is one of the key steps that could in-
fluence the availability of the released biomolecules 
and consequently the quality of the PRP [21]. Thrombin 
and/or calcium chloride is used as the most frequent 
activator before the administration of PRP in the da-
maged tissue [22]. The secretion of the active biomole-
cules begins 10 minutes after the activation of the 
platelets, and 95% of the growth factors are released in 
a period of 1 hour. Through the method of the active-
tion, the amount and the kind of the biomolecules is 
determined, which directly influences the tissue healing. 
The PRP activation strategy is determined by the type 
of procedure (open or laparoscopic), and the desired 
biological effect that is expected from the biological 
tissue [23].  
PRP for the treatment of ovarian infertility is a lower 
concentration (2.5x3 times) system. The process is 
carried out under strict aseptic conditions as well as 
optimum temperature regulations i.e. 21-24 C. PRP is 
In the last step, the volume immediately above the 
erythrocyte layer is collected. Calcium gluconate is 
used as an activator. After activation, in a period less 
than 2 min, approximately 3-5 ml of the PRP isinjected 
into the ovaries under transvaginal ultrasound guidance. 
Intervention is made following a protocol set by the 
IVF department. The entireintervention lasts 15 to 20 
minutes. The method of obtaining PRP is simple, 
minimally invasive and low cost. High concentration 
of growth factors and cytokines from PRP in the 
damaged tissue leads to balance between the anabolic 
and catabolic processes, optimizing tissue environment 
and favoring the process of tissue regeneration. 
 
Predicting the effectiveness of intraovarian PRP 
application 
 
FSH, estradiol and AMH levels are predictable of treat-
ment outcomes after PRP utilization. The treatment 
can lead to increasing the preantral follicles and in 





Even though PRP has a widespread usage in multiple 
medical spheres, unfortunately, there is still a lack of 
controlled clinical studies regarding the process. The 
limitation of this format should be taken into account 
i.e. sample size, RCT, design, etc. 
The main limitation of this study was the absence of 
previous data attesting the safety of PRP injection into 
human ovaries.Future larger trials would be required 
to corroborate the efficacy of PRP injection for treat-
ment ofovarian infertility, which would confirm the 




The authors reviewed the best available evidence for 
the usage of PRP in actual medical practice. Because 
the diagnosis of patients with lower ovarian reserves 
often leaves limited time for treating, the patients need 
to be given a choice. There is fair evidence that the cli-
nical and live birth rates are substantially different after 
the intraovarian application of PRP before IVF treatment. 
Further research is required to investigate whether dec-
reasing the level of FSH and increasing the number of 
antral follicles following intraovarian PRP injection is 
sustained.  
Future studies need to evaluate whether this approach 
may be especially beneficial in a specific subset of 
patients. 
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